MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts

LONDON, Jan.迷你倉 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:MediPoint: Drug-Eluting Balloons - EU Analysis and Market ForecastsMediPoint: Drug-Eluting Balloons - EU Analysis and Market ForecastsSummaryGlobalData has released its medical devices report, "MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts". The report provides in-depth insight into the use of DEB in the European Union (EU) for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.The DEB market in the five major EU countries including France, Germany, Italy, Spain and the UK was assessed to identify and determine whether the current unmet needs are addressed, understand the challenges of DEB angioplasty and evaluate the current and future adoption of DEB for select coronary and peripheral indications. The EU sales expectations are discussed through careful analysis of adoption patterns of using DEB in clinical practice.Clients can use this report to better understand the Scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report also provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData's team of industry experts.Scope- An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities. - Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data in the EU from 2010-2012 and forecast for seven years to 2019. - Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in the five major EU countries covered in the report, and implications of the drug-eluting balloon market. - Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability. - Analysis of the current and future market competition in the EU drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the DEB market in the EU. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EU DEB market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track device sales in the EU DEB market by disease and indication from 2010-2019. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Table of Contents1 Table of Contents 81.1 List of Tables 171.2 List of Figures 232 Introduction 262.1 Catalyst 273 Disease Overview 293.1 Overview 293.1.1 Coronary Artery Disease 293.1.2 Peripheral Artery Disease 293.2 Anatomy and Physiology 303.2.1 Coronary Arteries 303.2.2 Peripheral Arteries of the Lower Extremity 313.3 Pathophysiology 333.3.1 Coronary Artery Disease 333.3.2 Peripheral Artery Disease 343.4 Clinical Presentation 353.4.1 Symptoms 353.4.2 Risk Factors 383.4.3 Disease Classification 393.4.4 Diagnosis 403.4.5 Clinical Outcomes 433.5 Epidemiology 763.5.1 Coronary Artery Disease 763.5.2 Peripheral Artery Disease 793.6 Economic Impact of Coronary and Peripheral Artery Disease 823.6.1 Cost of Coronary Artery Disease 823.6.2 Cost of Peripheral Artery Disease 833.6.3 Treatment Costs of Coronary and Peripheral Artery Disease 844 Competitive Assessment 874.1 Overview 874.2 Product Profiles by Company 894.2.1 Aachen Resonance 904.2.2 B. Braun 924.2.3 Biotronik 994.2.4 Blue Medical 1024.2.5 Cardionovum 1084.2.6 C.R. Bard 1144.2.7 Concept Medical Research 1204.2.8 Cook Medical 1244.2.9 Eurocor 1264.2.10 Medrad (Bayer Healthcare) 1414.2.11 Medtronic 1434.2.12 Minvasys 1515 Unmet Needs 1545.1 Need for Better Clinical Outcomes in Specific Lesions 1545.1.1 Chronic Total Occlusions 1545.1.2 Small-Vessel Coronary Lesions 1555.1.3 Long Lesions 1555.1.4 Heavily-Calcified and Uncrossable/Undilatable Lesions 1565.1.5 Bifurcation Lesions 1565.2 Need for Better Revascularization of the Femoropopliteal Artery 1575.3 Difficulty in Treating the Infrapopliteal Artery 1595.4 Eliminating Mechanisms of Failure with Balloon Angioplasty 1605.5 Addressing Challenges of Stenting 1625.5.1 Risk of Post-Procedural Complications 1625.5.2 In-Stent Restenosis 1645.5.3 Stent-In-Stent Procedures 1655.5.4 Prolonged Dual Antiplatelet Therapy 1665.5.5 Lack of Homogenous Drug Distribution 1675.5.6 Delayed Healing 1675.5.7 Stent Fracture 1685.5.8 Negative Vessel Remodeling 1695.5.9 Long-Term Vessel Patency 1705.6 Need for Effective Therapy for Specific Patient Populations 1705.7 Lack of Clinical Data 1715.8 Addressing the Complications of Bypass Surgery 1715.9 Need to Improve Medical Therapy 1725.10 Comparative Studies on Exercise Therapy for PAD 1736 Pipeline Products 1746.1 Overview 1746.2 Pipeline by Stage of Development 1756.3 Pipeline Product Profiles 1776.3.1 NF-?B Decoy Oligo DEB 1776.3.2 Drug-Coated AngioSculpt 1796.3.3 BioPath 1826.3.4 BioStream 1836.3.5 Boston Scientific Drug-Coated Balloon 1846.3.6 Coroflex DEBlue 1856.3.7 Covidien Drug-Coated Balloon 1876.3.8 Caliber Therapeutics DEB 1896.3.9 Elixir Medical Corporation DCB 1906.3.10 LifeTech Scientific Corporation DEB 1906.3.11 Micell Technologies Drug-Coated Balloon 1906.3.12 Drug-Coated Chocolate DEB 1926.3.13 Passeo-18 Lux 1946.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 1956.3.15 WOMBAT DCB 1967 Clinical Trial Analysis 1987.1 Overview 1987.2 Clinical Trials to Watch 1987.2.1 Drug-Eluting Balloons 1987.2.2 Vascular Stents 2128 Industry Overview 2178.1 Procedure Trends 2178.1.1 Factors Contributing to the Rise of Coronary and Peripheral Interventions 2178.1.2 Coronary Artery Disease 2188.1.3 Peripheral Artery Disease 2198.2 Physician Decision-Making Process 2218.3 Market Access 2238.3.1 Regulatory Process 2248.3.2 Adoption 2268.3.3 Reimbursement Trends in the EU 2288.4 Regulatory Issues/Recalls 2338.4.1 Regulatory Issues 2338.4.2 Product Recalls 2338.5 Mergers and Acquisitions/Partnerships 2348.5.1 Biosensors International and Eurocor 2348.5.2 Boston Scientific Corporation and Guidant Corporation 2348.5.3 Covidien and ev3, CV Ingenuity 2358.5.4 C.R. Bard and Lutonix 2358.5.5 Micell Technologies and Maxcor Lifescience 2368.5.6 Medrad and Bayer 2368.5.7 Medtronic and Invatec 2379 Current and Future Players 2389.1 Overview 2389.2 Trends in Corporate Strategy 2399.3 Company Profiles 2429.3.1 Aachen Resonance 2429.3.2 AnGes MG 2439.3.3 AngioScore 2459.3.4 AVIDAL Vascular 2479.3.5 B. Braun 2499.3.6 Biosensors International 2519.3.7 Biotronik 2539.3.8 Blue Medical 2559.3.9 Boston Scientific Corporation 2579.3.10 Caliber Therapeutics 2599.3.11 Cardionovum 2619.3.12 Concept Medical Research 2639.3.13 Cook Medical 2659.3.14 Covidien 2679.3.15 C.R. Bard 2699.3.16 Elixir Medical Corporation 2719.3.17 Eurocor 2739.3.18 LifeTech Scientific Corporation 2759.3.19 Medtronic 2779.3.20 Micell Technologies 2799.3.21 Minvasys 2809.3.22 TriReme Medical 2829.3.23 Vascular Nanotransfer Technologies 28410 Market Drivers, Opportunities, Barriers and Substitutes 28610.1 Market Drivers 28610.1.1 Rising Prevalence of Disease 28710.1.2 Viable Treatment for Select Indications 28810.1.3 No Metal Left Behind 29310.1.4 Avoid Stent-in-Stent Procedures 29410.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 29510.1.6 Enhanced Vessel Healing and Better Patency 29510.1.7 Technical Feasibility of Future Interventions 29610.1.8 DEB as an Adjunctive Therapy 29710.1.9 Limb Amputation 29710.1.10 Cost Savings 29810.1.11 Availability of Long-Term and Cost-Effective Data 29910.1.12 Launch of DEB in the US 29910.2 Opportunities 30010.2.1 Improve DEB Design 30010.2.2 DEB Hybrid Systems (DEB + Stent) 30410.2.3 Target Indications Where Stenting is Not Satisfactory 30410.2.4 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 30710.2.5 Target Challenging Patient Populations 30910.2.6 Launch DEB in the Japanese Market 31010.2.7 Emerging Markets 31010.3 Market Barriers 31110.3.1 Slow Adoption 31110.3.2 High Selling Prices 31510.3.3 Lack of Reimbursement 31610.3.4 US FDA Regulatory Challenges 31710.3.5 Healthcare Cost-Cutting and Reimbursement 31810.3.6 Availability of Venture Capital 31910.3.7 Medical Device Excise Tax 32010.4 Market Substitutes 32010.4.1 Vascular Stents 32010.4.2 Liquid Drug Delivery Catheter 32411 Drug-Eluting Balloon Market Analysis 32711.1 Global Market Overview 32711.2 Market Analysis by Type of Disease 32811.2.1 Coronary Artery Disease 32811.2.2 Peripheral Artery Disease in the Lower Extremity 32911.3 Market Distribution by Indication 33211.4 Primary Versus Adjunctive Therapy 33411.5 Comparative Market Analysis 33611.5.1 Coronary Artery Disease 33611.5.2 Peripheral Artery Disease in the Lower Extremity 33812 Country Outlooks & Forecasts 34012.1 Overview 34012.2 France 34212.2.1 Overview 34212.2.2 Market Analysis 34212.3 Germany 34412.3.1 Overview 34412.3.2 Market Analysis 34412.4 Italy 34812.4.1 Overview 34812.4.2 Market Analysis 34812.5 Spain 35112.5.1 Overview 35112.5.2 Market Analysis 35112.6 United Kingdom 35312.6.1 Overview 35312.6.2 Market Analysis 35313 Appendix 35613.1 Bibliography 35613.2 Abbreviations 38213.3 Report Methodology 38613.3.1 Overview 38613.3.2 Coverage 38613.3.3 Secondary Research 38613.3.4 Forecasting Methodology 38713.4 Physicians and Specialists Included in this Study 38913.5 Physician Survey 39213.6 About the Authors 39313.6.1 Analysts 39313.6.2 Global Head of Healthcare 39413.7 About MediPoint 39513.8 About GlobalData 39513.9 Disclaimer 395List of TablesTable 1: Classification Systems for Determining the Severity of PAD Symptoms 37Table 2: Risk Factors Associated with CAD and PAD 38Table 3: Types of Atherosclerotic Lesions 40Table 4: Treatment Guidelines to Improve the Symptoms of CAD* 45Table 5: TASC II Classification of Iliac Artery Lesions 46Table 6: TASC II Classification of Femoropopliteal Artery Lesions 47Table 7: TASC II Classification of Infrapopliteal Artery Lesions 48Table 8: Types of Coronary Artery Bypass Grafting 59Table 9: Complications of Coronary/Peripheral Artery Bypassmini storageSurgery 60Table 10: Indications for Using Drug-Eluting Balloons 64Table 11: Drug-Eluting Balloon Coating Characteristics 66Table 12: Drugs Incorporated Into Drug-Eluting Stents 69Table 13: Types of Lesions Treated Using Atherectomy 72Table 14: Prevalence of CAD in the Population Age ?65 Years in the EU (millions), 2010-2019 77Table 15: Prevalence of PAD in the Population Age ?65 Years in the EU (millions), 2010-2019 79Table 16: Direct and Indirect Healthcare Costs 82Table 17: Healthcare Expenditures ($bn) for CAD in the Five Major EU Countries, 2006 83Table 18: Healthcare Expenditures ($bn) for PAD in the EU 83Table 19: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010-2019 ($US) 85Table 20: EU DEB Market ($m) for Treating Coronary and Peripheral Artery Disease, 2012 87Table 21: Marketed DEB Products 89Table 22: Elutax SV Product Portfolio 90Table 23: Elutax SV SWOT Analysis, 2013 92Table 24: SeQuent Please Product Portfolio 93Table 25: SeQuent Please SWOT Analysis, 2013 98Table 26: Pantera Lux Product Portfolio 99Table 27: Pantera Lux SWOT Analysis, 2013 101Table 28: Pioneer Product Portfolio 102Table 29: Pioneer SWOT Analysis, 2013 104Table 30: Protege Product Portfolio 105Table 31: Protege SWOT Analysis, 2013 108Table 32: Restore DEB Product Portfolio 109Table 33: Restore DEB SWOT Analysis, 2013 110Table 34: Legflow DEB Product Portfolio 111Table 35: Legflow DEB SWOT Analysis, 2013 113Table 36: Other DEB Products Developed by Cardionovum 114Table 37: Lutonix Product Portfolio 115Table 38: Lutonix SWOT Analysis, 2013 120Table 39: Magic Touch Product Portfolio 121Table 40: Magic Touch SWOT Analysis, 2013 123Table 41: Advance 18 PTX Product Portfolio 124Table 42: Advance 18 PTX SWOT Analysis, 2013 126Table 43: Dior Product Portfolio 127Table 44: Dior SWOT Analysis, 2013 133Table 45: Freeway Family of DEB Product Portfolio 134Table 46: Freeway Family of DEB SWOT Analysis, 2013 137Table 47: Magical Product Portfolio 138Table 48: Magical SWOT Analysis, 2013 140Table 49: Cotavance Product Portfolio 141Table 50: Cotavance SWOT Analysis, 2013 143Table 51: IN.PACT Family DEB Product Portfolio 144Table 52: IN.PACT SWOT Analysis, 2013 151Table 53: Danubio Product Portfolio 152Table 54: Danubio SWOT Analysis, 2013 153Table 55: Global DEB Pipeline Products 176Table 56: NF-?B Decoy Oligo DEB SWOT Analysis, 2013 179Table 57: AngioSculpt SWOT Analysis, 2013 181Table 58: BioPath SWOT Analysis, 2013 183Table 59: BioStream SWOT Analysis, 2013 184Table 60: Boston Scientific DEB SWOT Analysis, 2013 185Table 61: Coroflex DEBlue SWOT Analysis, 2013 187Table 62: Covidien DCB SWOT Analysis, 2013 189Table 63: Micell Technologies' DCB SWOT Analysis, 2013 191Table 64: Drug-Coated Chocolate DEB SWOT Analysis, 2013 193Table 65: Passeo-18 Lux SWOT Analysis, 2013 195Table 66: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013 196Table 67: WOMBAT DCB SWOT Analysis, 2013 197Table 68: Aachen Resonance Company Profile 242Table 69: Aachen Resonance, Marketed DEB Product 243Table 70: Aachen Resonance SWOT Analysis, 2013 243Table 71: AnGes MG Company Profile 244Table 72: AnGes MG, Pipeline DEB Product 245Table 73: AnGes MG SWOT Analysis, 2013 245Table 74: AngioScore Company Profile 246Table 75: AngioScore, Pipeline DEB Product 246Table 76: AngioScore SWOT Analysis, 2013 247Table 77: AVIDAL Vascular Company Profile 247Table 78: AVIDAL Vascular, Pipeline DEB Product 248Table 79: AVIDAL Vascular SWOT Analysis, 2013 249Table 80: B. Braun Company Profile 249Table 81: B. Braun, Marketed and Pipeline DEB Products 250Table 82: B. Braun SWOT Analysis, 2013 251Table 83: Biosensors International Company Profile 252Table 84: Biosensors International, Pipeline DEB Products 252Table 85: Biosensors International SWOT Analysis, 2013 253Table 86: Biotronik Company Profile 254Table 87: Biotronik, Marketed and Pipeline DEB Products 254Table 88: Biotronik SWOT Analysis, 2013 255Table 89: Blue Medical Company Profile 256Table 90: Blue Medical, Marketed DEB Products 257Table 91: Blue Medical SWOT Analysis, 2013 257Table 92: Boston Scientific Corporation Company Profile 258Table 93: Boston Scientific Corporation, Pipeline DEB Product 258Table 94: Boston Scientific Corporation SWOT Analysis, 2013 259Table 95: Caliber Therapeutics Company Profile 259Table 96: Caliber Therapeutics, Pipeline DEB Product 260Table 97: Caliber Therapeutics SWOT Analysis, 2013 261Table 98: Cardionovum Company Profile 261Table 99: Cardionovum, Marketed and Pipeline DEB Products 262Table 100: Cardionovum SWOT Analysis, 2013 263Table 101: Concept Medical Research Company Profile 263Table 102: Concept Medical Research, Marketed DEB Product 264Table 103: Concept Medical Research SWOT Analysis, 2013 265Table 104: Cook Medical Company Profile 265Table 105: Cook Medical, Marketed DEB Product 266Table 106: Cook Medical SWOT Analysis, 2013 267Table 107: Covidien Company Profile 268Table 108: Covidien, Pipeline DEB Product 268Table 109: Covidien SWOT Analysis, 2013 269Table 110: C.R. Bard Company Profile 269Table 111: C.R. Bard, Marketed DEB Products 270Table 112: C.R. Bard SWOT Analysis, 2013 271Table 113: Elixir Medical Corporation Company Profile 271Table 114: Elixir Medical Corporation, Pipeline DEB Product 272Table 115: Elixir Medical Corporation SWOT Analysis, 2013 272Table 116: Eurocor Company Profile 273Table 117: Eurocor, Marketed DEB Products 274Table 118: Eurocor SWOT Analysis, 2013 274Table 119: LifeTech Scientific Corporation Company Profile 275Table 120: LifeTech Scientific, Pipeline DEB Product 276Table 121: LifeTech Scientific SWOT Analysis, 2013 276Table 122: Medtronic Company Profile 277Table 123: Medtronic, Marketed DEB Products 278Table 124: Medtronic SWOT Analysis, 2013 278Table 125: Micell Technologies Company Profile 279Table 126: Micell Technologies, Pipeline DEB Product 280Table 127: Micell Technologies SWOT Analysis, 2013 280Table 128: Minvasys Company Profile 281Table 129: Minvasys, Marketed DEB Product 281Table 130: Minvasys SWOT Analysis, 2013 282Table 131: TriReme Medical Company Profile 282Table 132: TriReme Medical, Pipeline DEB Product 283Table 133: TriReme Medical SWOT Analysis, 2013 284Table 134: Vascular Nanotransfer Technologies Company Profile 284Table 135: Vascular Nanotransfer Technologies, Pipeline DEB Product 285Table 136: Vascular Nanotransfer Technologies SWOT Analysis, 2013 285Table 137: EU Coronary and Peripheral DEB Market ($m) Forecast, 2010-2019 328Table 138: EU DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 329Table 139: Percent of Patients with CAD or PAD Receiving Stenting with DEB Angioplasty, EU, 2012 and 2018 (N=56) 334Table 140: DEB Sales ($m) Forecast for France, 2010-2019 342Table 141: DEB Sales ($m) Forecast for Germany, 2010-2019 345Table 142: DEB Sales ($m) Forecast for Italy, 2010-2019 348Table 143: DEB Sales ($m) Forecast for Spain, 2010-2019 352Table 144: DEB Sales ($m) Forecast for UK, 2010-2019 354Table 145: Physicians Surveyed, By Country 391.2 List of FiguresFigure 1: Coronary Arteries of the Human Heart 30Figure 2: Peripheral Arteries of the Lower Extremity 31Figure 3: Pathophysiology of Coronary Artery Disease 33Figure 4: Pathophysiology of Peripheral Artery Disease 34Figure 5: Treatment Modalities - Coronary Artery Disease 50Figure 6: Percent of Patients with CAD Who Receive Each Therapy Option Only, EU, 2012 and 2019 (N=32) 51Figure 7: Treatment Modalities - Peripheral Artery Disease 52Figure 8: Percent of Patients with PAD Who Receive Each Therapy Option Only, EU, 2012 (N=24) 53Figure 9: Percent of Patients with PAD Who Receive Each Therapy Option Only, EU, 2012 (N=24) 54Figure 10: Drug-Eluting Balloon 62Figure 11: Types of Stents Used to Treat CAD and PAD 68Figure 12: Bare Metal Stent 68Figure 13: Drug-Eluting Stent 69Figure 14: Covered Stents 70Figure 15: Bioabsorbable Stent - Remedy 71Figure 16: Types of Atherectomy 73Figure 17: Prevalence of CAD in the Population Age ?65 Years in the EU (millions), 2010-2019 77Figure 18: Prevalence of PAD in the Population Age ?65 Years in the EU (millions), 2010-2019 80Figure 19: Healthcare Expenditures ($bn) for PAD in the EU 84Figure 20: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010-2019 ($US) 86Figure 21: EU DEB Market Share for Treating Peripheral Artery Disease in the Lower Extremity, 2012 88Figure 22: Image of the Protege DEB 106Figure 23: Percent of CAD and PAD Patients with Acute Vessel Recoil After Standard Balloon Angioplasty, EU, 2012 and 2018 (N=56) 161Figure 24: Percent of CAD and PAD Patients with Thrombosis After Stenting, EU, 2012 and 2018 (N=56) 163Figure 25: Percent of CAD and PAD Patients with ISR, EU, 2012 and 2018 (N=56) 164Figure 26: Percent of CAD and PAD Patients Who Receive Stent-In-Stent Procedures, EU, 2012 and 2018 (N=56) 166Figure 27: Percent of CAD and PAD Patients with Stent Fracture, EU, 2012 and 2018 (N=56) 169Figure 28: Global DEB Pipeline Products by Stage of Development, 2013 175Figure 29: AngioSculpt Scoring Balloon Expansion Profile 180Figure 30: Drug-Coated Chocolate DEB 192Figure 31: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, EU*, 2010-2019 219Figure 32: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 220Figure 33: Population (? 65 years) with PAD Receiving DEB Angioplasty in the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 221Figure 34: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012 238Figure 35: DEB Market for Each Type of Disease, Company Share (%), 2012 240Figure 36: Importance of Each Therapy Attribute in Adopting DEB for the Treatment of CAD and PAD, Global, 2012 (N=112) 301Figure 37: EU DEB Market ($m) for Treating Coronary Artery Disease and Peripheral Artery Disease in the Lower Extremity, 2010-2019 327Figure 38: EU DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 330Figure 39: EU DEB Market Share for Peripheral Artery Revascularization in the Lower Extremity , 2012 and 2019 331Figure 40: EU DEB Market Distribution (%) by Indication, 2012 and 2018 (N=56) 333Figure 41: Percent of Patients with CAD Receiving Each Type of Interventional Technique Only, EU, 2018 (N=32) 337Figure 42: Percent of Patients with Lower Limb PAD Receiving Each Type of Interventional Technique Only, EU, 2018 (N=24) 338Figure 43: EU DEB Market Revenue ($m), 2012 and 2019 341Figure 44: French DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 343Figure 45: German DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 345Figure 46: Italian DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 349Figure 47: Spanish DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 352Figure 48: UK DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 355Companies MentionedAachen ResonanceAnGes MGAngioScoreAVIDAL VascularB. BraunBiosensors InternationalBiotronikBlue MedicalBoston Scientific CorporationCaliber TherapeuticsCardionovumConcept Medical ResearchCook MedicalCovidienC.R. BardElixir Medical CorporationEurocorLifeTech Scientific CorporationMedtronicMicell TechnologiesMinvasysTriReme MedicalVascular Nanotransfer TechnologiesRead the full report:MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts .reportbuyer.com/pharma_healthcare/diseases/medipoint_drug_eluting_balloons_eu_analysis_market_forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=PathologyFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: .reportbuyer.comReportBuyerWeb site: .reportbuyer.com/self storage